var data={"title":"Ixazomib: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Ixazomib: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/791437?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=ixazomib-patient-drug-information\" class=\"drug drug_patient\">see &quot;Ixazomib: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45755758\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Ninlaro</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45684236\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antineoplastic Agent, Proteasome Inhibitor</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45759747\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Note:</b> ANC should be &ge;1,000/mm<sup>3</sup>, platelets should be &ge;75,000/mm<sup>3</sup>, and nonhematologic toxicities should be at baseline or &le; grade 1 (per prescriber discretion) prior to initiating a new cycle of therapy. Consider antiviral prophylaxis to decrease the risk of herpes zoster reactivation.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Multiple myeloma:</b> Oral: 4 mg once weekly on days 1, 8, and 15 of a 28-day treatment cycle (in combination with lenalidomide and dexamethasone); continue until disease progression or unacceptable toxicity (Moreau 2016).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Missed doses:</i> If a dose is delayed or missed, administer only if the next scheduled dose is &ge;72 hours away. Do not take a missed dose within 3 days of the next scheduled dose; do not double up on doses to make up for the missed dose. If vomiting occurs, do not repeat the dose; resume dosing at the next scheduled dose.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45759748\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">The International Myeloma Working Group (IMWG) recommends the use of the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation (preferred) or the Modification of Diet in Renal Disease (MDRD) formula to evaluate renal function estimation in multiple myeloma patients with a stable serum creatinine (Dimopoulos 2016).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Preexisting renal impairment:</i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl &ge;30 mL/minute: The IMWG suggest that ixazomib (in combination with lenalidomide and dexamethasone) may be safely administered to patients with a CrCl &ge;30 mL/minute (Dimopoulos 2016).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl &lt;30 mL/minute: Reduce initial dose to 3 mg once weekly on days 1, 8, and 15 of a 28-day treatment cycle</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">ESRD requiring dialysis: Reduce initial dose to 3 mg once weekly on days 1, 8, and 15 of a 28-day treatment cycle; ixazomib is not dialyzable and may be administered without regarding to dialysis timing.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Renal toxicity during treatment:</i> Grade 3 or 4 toxicity: Withhold ixazomib until recovery to baseline or improvement to &le; grade 1 (at prescriber's discretion). If attributable to ixazomib, resume ixazomib at the next lower dose.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45759749\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Preexisting hepatic impairment:</i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Mild impairment (total bilirubin &le; ULN and AST &gt; ULN or total bilirubin &gt;1 to 1.5 times ULN and any AST): No dosage adjustment is necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Moderate (total bilirubin &gt;1.5 to 3 times ULN) or severe (total bilirubin &gt;3 times ULN) impairment: Reduce initial dose to 3 mg once weekly on days 1, 8, and 15 of a 28-day treatment cycle</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Hepatotoxicity during treatment:</i> Grade 3 or 4 toxicity: Withhold ixazomib until recovery to baseline or improvement to &le;grade 1 (at prescriber&rsquo;s discretion). If attributable to ixazomib, resume ixazomib at the next lower dose.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45759750\" class=\"block dot drugH1Div\"><span class=\"drugH1\">Dosing: Adjustment for Toxicity</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Also refer to Lenalidomide monograph for dosage modification recommendations.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Recommended ixazomib dosage reductions for toxicity:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Initial starting dose: 4 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">First dose reduction: 3 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Second dose reduction: 2.3 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">If unable to tolerate 2.3 mg, discontinue ixazomib</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Hematologic toxicity:</i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Neutropenia:</i> ANC &lt;500/mm<sup>3</sup>: Withhold ixazomib and lenalidomide until ANC is &ge;500/mm<sup>3</sup>. Consider adding growth-colony stimulating factor (G-CSF). Upon recovery, resume lenalidomide at the next lower dose and resume ixazomib at the dose used prior to therapy interruption. If neutropenia to &le;500/mm<sup>3</sup> recurs, interrupt ixazomib and lenalidomide until ANC is &ge;500/mm<sup>3</sup>. Following recovery, resume ixazomib at the next lower dose and resume lenalidomide at the dose used prior to therapy interruption. For additional occurrences, alternate dose modification of lenalidomide and ixazomib.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Thrombocytopenia:</i> Platelet count &lt;30,000/mm<sup>3</sup>: Withhold ixazomib and lenalidomide until platelet count is &ge;30,000/mm<sup>3</sup>. Upon recovery, resume lenalidomide at the next lower dose and resume ixazomib at the dose used prior to therapy interruption. If thrombocytopenia to &le;30,000/mm<sup>3</sup> recurs, interrupt ixazomib and lenalidomide until platelets are &ge;30,000/mm<sup>3</sup>. Following recovery, resume ixazomib at the next lower dose and resume lenalidomide at the dose used prior to therapy interruption. For additional occurrences, alternate dose modification of lenalidomide and ixazomib.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Nonhematologic toxicity:</i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Dermatologic toxicity:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Grade 2 or 3 rash: Withhold lenalidomide until rash recovers to &le; grade 1. Upon recovery, resume lenalidomide at the next lower dose and resume ixazomib at the dose used prior to therapy interruption. If grade 2 or 3 rash recurs, interrupt ixazomib and lenalidomide until rash recovers to &le; grade 1. Following recovery, resume ixazomib at the next lower dose and resume lenalidomide at the dose used prior to therapy interruption. For additional occurrences, alternate dose modification of lenalidomide and ixazomib.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Grade 4 rash: Discontinue treatment regimen.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Peripheral neuropathy:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Grade 1 (with pain) or grade 2: Interrupt ixazomib until peripheral neuropathy recovers to &le; grade 1 without pain or to baseline. Upon recovery, resume ixazomib at the dose used prior to therapy interruption.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Grade 2 (with pain) or grade 3: Withhold ixazomib until recovery to baseline or improvement to &le; grade 1 (at prescriber&rsquo;s discretion). Following recovery, resume ixazomib at the next lower dose.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Grade 4: Discontinue treatment regimen.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Other toxicities (nonhematologic):</i> Grade 3 or 4 toxicity: Withhold ixazomib until recovery to baseline or improvement to &le;grade 1 (at prescriber&rsquo;s discretion). If attributable to ixazomib, resume ixazomib at the next lower dose. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45755759\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Ninlaro: 2.3 mg, 3 mg, 4 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45755757\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45760315\" class=\"block accres drugH1Div\"><span class=\"drugH1\">Prescribing and Access Restrictions</span>\n    <p style=\"text-indent:0em;display:inline\">Available through specialty pharmacies and distributors. Further information may be obtained from the manufacturer, Takeda Oncology, at 1-800-390-5663 or at http://www.ninlarohcp.com.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45759752\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral: Administer on the same day of the week and at approximately the same time on that day; take at least 1 hour before or at least 2 hours after eating. Swallow capsule whole; do not crush, chew, or open the capsule. Avoid skin or eye exposure to capsule contents. If skin contact occurs, wash thoroughly with soap and water; if eye contact occurs, flush thoroughly with water. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49104524\" class=\"block hazard drugH1Div\"><span class=\"drugH1\">Hazardous Drugs Handling Considerations</span>\n    <p style=\"text-indent:0em;\">Hazardous agent (NIOSH 2016 [group 1]).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage. NIOSH recommends single gloving for administration of intact tablets or capsules (NIOSH 2016).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45684227\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Multiple myeloma:</b> Treatment of multiple myeloma (in combination with lenalidomide and dexamethasone) in patients who have received at least one prior therapy</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45760313\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Ixazomib may be confused with bortezomib, carfilzomib, idelalisib</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its lists of drug classes which have a heightened risk of causing significant patient harm when used in error.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45701086\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse reaction percentages reported as part of a combination regimen with lenalidomide and dexamethasone.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Peripheral edema (25%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Peripheral neuropathy (28%; grade 3: 2%), peripheral sensory neuropathy (19%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Skin rash (19%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Diarrhea (42%), constipation (34%), nausea (26%), vomiting (22%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Thrombocytopenia (78%; grades 3/4: 26%), neutropenia (67%; grades 3/4: 26%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Back pain (21%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ophthalmic: Eye disease (26%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Upper respiratory tract infection (19%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic: Hepatic insufficiency (6%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Herpes zoster (4%; &lt;1% with antiviral prophylaxis)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ophthalmic: Blurred vision (6%), conjunctivitis (6%), xerophthalmia (5%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Cholestatic hepatitis, hepatocellular hepatitis, hepatotoxicity, liver steatosis, peripheral motor neuropathy, reversible posterior leukoencephalopathy syndrome, Stevens-Johnson syndrome, Sweet's syndrome, thrombotic thrombocytopenic purpura, transverse myelitis, tumor lysis syndrome</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45684232\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">There are no contraindications listed in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45759730\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bone marrow suppression: Neutropenia and thrombocytopenia were reported commonly in clinical trials; grade 3 and 4 toxicity was also observed. Platelet nadirs generally occurred between days 14 to 21 of each cycle with a recovery to baseline by the start of the subsequent cycle. Monitor platelet counts at least monthly during treatment, and consider more frequent monitoring during the initial 3 cycles. May require therapy interruption, dosage reduction and/or platelet transfusions. Monitor complete blood counts (with differential) for neutropenia; therapy interruption or dosage modification may be necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Dermatologic toxicity: Rash was reported with ixazomib use; the majority of cases were grade 1 or 2 (grade 3 rash was observed in a small number of patients). Maculopapular and macular rashes were the most commonly reported cutaneous reactions. Monitor for dermatologic toxicity and manage with supportive care or with dosage modification of ixazomib and/or lenalidomide (for grade 2 or higher toxicity).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Gastrointestinal toxicity: Diarrhea, constipation, nausea, and vomiting have been reported. Antidiarrheals,  antiemetics, and supportive care may be required to manage toxicity. Dosage adjustment is recommended for grade 3 or 4 symptoms.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatotoxicity: Drug-induced livery injury, hepatocellular injury, hepatic steatosis, hepatitis cholestatic and hepatotoxicity were reported rarely in clinical trials. Monitor liver enzymes regularly; may require dosage adjustment for grade 3 or 4 toxicity.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Herpes zoster infection: Herpes zoster infection has been reported; patients receiving antiviral prophylaxis had a lower incidence of infection. Consider antiviral prophylaxis during ixazomib treatment to decrease the risk of herpes zoster reactivation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Peripheral edema: Peripheral edema was reported in one-quarter of patients receiving ixazomib (generally grade 1 or 2 reactions). If peripheral edema occurs, evaluate for potential underlying causes and provide supportive care. If necessary, grade 3 or 4 symptoms may require dosage adjustment of dexamethasone and/or ixazomib.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Peripheral neuropathy: Peripheral neuropathy (mostly grade 1 or 2) was observed. Peripheral sensory neuropathy was the most commonly reported symptom, while peripheral motor neuropathy was rarely seen. Monitor closely for signs/symptoms of neuropathy; may require dosage adjustment (of ixazomib and/or lenalidomide) or treatment discontinuation.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Reduced initial doses are recommended for patients with moderate and severe hepatic impairment (exposure is increased).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Reduced initial doses are recommended for patients with CrCl less than 30 mL/minute or end stage renal disease requiring dialysis (exposure is increased). Concomitant lenalidomide may also require dose reduction.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues: </i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45733007\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP3A4 (major), P-glycoprotein/ABCB1; <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45733004\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=105607&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Myelosuppressive Agents may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bosentan: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chloramphenicol (Ophthalmic): May enhance the adverse/toxic effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for neutropenia may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Moderate): May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Strong): May decrease the serum concentration of Ixazomib.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dabrafenib: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Seek alternatives to the CYP3A4 substrate when possible.  If concomitant therapy cannot be avoided, monitor clinical effects of the substrate closely (particularly therapeutic effects).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferasirox: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferiprone: Myelosuppressive Agents may enhance the neutropenic effect of Deferiprone. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dipyrone: May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Estrogen Derivatives (Contraceptive): Ixazomib may decrease the serum concentration of Estrogen Derivatives (Contraceptive). More specifically, use of ixazomib with dexamethasone may decrease the serum concentrations of estrogen derivative contraceptives.  Management: Patients of childbearing potential should use a nonhormonal barrier contraceptive during and 90 days following ixazomib treatment.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pitolisant: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Combined use of pitolisant with a CYP3A4 substrate that has a narrow therapeutic index should be avoided. Other CYP3A4 substrates should be monitored more closely when used with pitolisant.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Progestins (Contraceptive): Ixazomib may decrease the serum concentration of Progestins (Contraceptive). More specifically, use of ixazomib with dexamethasone may decrease the serum concentrations of contraceptive progestins.  Management: Patients of childbearing potential should use a nonhormonal barrier contraceptive during and 90 days following ixazomib treatment.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Promazine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sarilumab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Siltuximab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">St John's Wort: May decrease the serum concentration of Ixazomib.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45759728\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Based on animal data and the mechanism of action, ixazomib is expected to cause fetal harm if used during pregnancy. Males and females of reproductive potential should use effective contraception during therapy and for 90 days after the last dose.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">When used for the treatment of multiple myeloma, ixazomib is indicated to be used with lenalidomide and dexamethasone. Lenalidomide is contraindicated for use during pregnancy (refer to lenalidomide monograph for details). Dexamethasone is a weak to moderate CYP3A4 inducer, and may decrease the efficacy of hormonal contraceptives. Women using hormonal contraception should also use a barrier method.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45759729\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if ixazomib is excreted into breast milk. Due to the potential for serious adverse events in a nursing infant, the manufacturer recommends that breast-feeding be discontinued during therapy and for 90 days after the last ixazomib dose.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45759754\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Platelet counts at least monthly during treatment (consider more frequent monitoring during the first 3 cycles), complete blood count (with differential) as clinically necessary, renal and liver function tests; signs/symptoms of gastrointestinal and dermatologic toxicity; signs/symptoms of peripheral neuropathy and peripheral edema.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45759733\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Ixazomib reversibly inhibits proteasomes, enzyme complexes which regulate protein homeostasis within the cell. Specifically, it reversibly inhibits chymotrypsin-like activity of the beta 5 subunit of the 20S proteasome, leading to activation of signaling cascades, cell-cycle arrest, and apoptosis.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45759735\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: High-fat meals decreased AUC by 28% and C<sub>max</sub> by 69%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: 543 L</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: 99% to plasma proteins</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Likely hepatic via multiple CYP enzymes and non-CYP proteins. At clinically relevant concentrations, no specific CYP isoform contributes predominantly to metabolism; possible CYP isoforms involved in metabolism include CYP3A4, 1A2, 2B6, 2C8, 2D6, 2C19, and 2C9.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bioavailability: 58%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: Terminal: 9.5 days</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak: Median: 1 hour</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (62%; &lt;3.5% as unchanged drug); Feces (22%)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46105221\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Ninlaro Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2.3 mg (1): $3,787.20</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">3 mg (1): $3,787.20</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4 mg (1): $3,787.20</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49128942\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Ninlaro (AT, AU, BB, CZ, DE, DK, EE, HR, IL, JP, LT, LU, LV, NO, PL, PT, RO, SK)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Dimopoulos MA, Sonneveld P, Leung N, et al. International Myeloma Working Group recommendations for the diagnosis and management of myeloma-related renal impairment. <i>J Clin Oncol</i>. 2016;34(13):1544-1557.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ixazomib-drug-information/abstract-text/26976420/pubmed\" target=\"_blank\" id=\"26976420\">26976420</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Moreau P, Masszi T, Grzasko N, et al. Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma. <i>N Engl J Med.</i> 2016;374(17):1621-1634.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ixazomib-drug-information/abstract-text/27119237/pubmed\" target=\"_blank\" id=\"27119237\">27119237</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ninlaro (ixazomib) [prescribing information]. Cambridge, MA: Takeda Pharmaceutical Company Limited; November 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href=\"http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf\" target=\"_blank\">http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf</a>. Updated September 2016. Accessed October 5, 2016.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 105607 Version 40.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F45755758\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F45684236\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F45759747\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F45759748\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F45759749\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adjustment for Toxicity\" href=\"#F45759750\" class=\"outlineLink\">Dosing: Adjustment for Toxicity</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F45755759\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F45755757\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Prescribing and Access Restrictions\" href=\"#F45760315\" class=\"outlineLink\">Prescribing and Access Restrictions</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F45759752\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Hazardous Drugs Handling Considerations\" href=\"#F49104524\" class=\"outlineLink\">Hazardous Drugs Handling Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F45684227\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F45760313\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F45701086\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F45684232\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F45759730\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F45733007\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F45733004\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F45759728\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F45759729\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F45759754\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F45759733\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F45759735\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F46105221\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F49128942\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/105607|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=ixazomib-patient-drug-information\" class=\"drug drug_patient\">Ixazomib: Patient drug information</a></li></ul></div></div>","javascript":null}